{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:16:56Z","timestamp":1791649016284,"version":"4.3.4"},"reference-count":58,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["HHSF223201310144C"],"award-info":[{"award-number":["HHSF223201310144C"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.xphs.2016.02.020","type":"journal-article","created":{"date-parts":[[2016,3,25]],"date-time":"2016-03-25T11:16:42Z","timestamp":1458904602000},"page":"2804-2814","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["The Evaluation of In\u00a0Vitro Drug Dissolution of Commercially Available Oral Dosage Forms for Itraconazole in Gastrointestinal Simulator With Biorelevant Media"],"prefix":"10.1016","volume":"105","author":[{"given":"Kazuki","family":"Matsui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Tsume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory E.","family":"Amidon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon L.","family":"Amidon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.xphs.2016.02.020_bib1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1056-8719(00)00107-6","article-title":"Drug-like properties and the causes of poor solubility and poor permeability","volume":"44","author":"Lipinski","year":"2000","journal-title":"J\u00a0Pharmacol Toxicol Methods"},{"issue":"5","key":"10.1016\/j.xphs.2016.02.020_bib2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ejps.2007.05.110","article-title":"When poor solubility becomes an issue: from early stage to proof of concept","volume":"31","author":"Stegemann","year":"2007","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2016.02.020_bib3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jsps.2013.02.001","article-title":"Comparative in\u00a0vitro dissolution study of carbamazepine immediate-release products using the USP paddles method and the flow-through cell system","volume":"22","author":"Medina","year":"2014","journal-title":"Saudi Pharm J"},{"issue":"10","key":"10.1016\/j.xphs.2016.02.020_bib4","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1211\/jpp.58.10.0004","article-title":"Fast-dissolving microparticles fail to show improved oral bioavailability","volume":"58","author":"Wong","year":"2006","journal-title":"J\u00a0Pharm Pharmacol"},{"key":"10.1016\/j.xphs.2016.02.020_bib5","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ejps.2013.08.024","article-title":"In\u00a0vitro models for the prediction of in\u00a0vivo performance of oral dosage forms","volume":"57","author":"Kostewicz","year":"2014","journal-title":"Eur J Pharm Sci"},{"issue":"11","key":"10.1016\/j.xphs.2016.02.020_bib6","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1002\/jps.24112","article-title":"Evaluation of a three compartment in\u00a0vitro gastrointestinal simulator dissolution apparatus to predict in\u00a0vivo dissolution","volume":"103","author":"Takeuchi","year":"2014","journal-title":"J\u00a0Pharm Sci"},{"issue":"6","key":"10.1016\/j.xphs.2016.02.020_bib7","first-page":"224","article-title":"Dissolution effect of gastric and intestinal pH for a BCS class II drug, pioglitazone: new in\u00a0vitro dissolution system to predict in\u00a0vivo dissolution","volume":"5","author":"Tsume","year":"2013","journal-title":"J\u00a0Bioequiv Availab"},{"key":"10.1016\/j.xphs.2016.02.020_bib8","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejps.2015.05.013","article-title":"In\u00a0vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in\u00a0vivo dissolution of a weak base drug, dasatinib","volume":"76","author":"Tsume","year":"2015","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2016.02.020_bib9","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1021\/acs.molpharmaceut.5b00135","article-title":"In\u00a0vitro dissolution of fluconazole and dipyridamole in gastrointestinal simulator (GIS), predicting in\u00a0vivo dissolution and drug-drug interaction caused by acid-reducing agents","volume":"12","author":"Matsui","year":"2015","journal-title":"Mol Pharm"},{"issue":"12","key":"10.1016\/j.xphs.2016.02.020_bib10","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1007\/s11095-011-0506-6","article-title":"Precipitation in and supersaturation of contents of the upper small intestine after administration of two weak bases to fasted adults","volume":"28","author":"Psachoulias","year":"2011","journal-title":"Pharm Res"},{"key":"10.1016\/j.xphs.2016.02.020_bib11","unstructured":"Janssen Pharmaceuticals. Prescription information on Sporanox capsule. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/020083s053lbl.pdf. Accessed December 18, 2015."},{"issue":"3","key":"10.1016\/j.xphs.2016.02.020_bib12","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","article-title":"A\u00a0theoretical basis for a biopharmaceutic drug classification: the correlation of in\u00a0vitro drug product dissolution and in\u00a0vivo bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharm Res"},{"issue":"3-4","key":"10.1016\/j.xphs.2016.02.020_bib13","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ejps.2006.11.015","article-title":"The use of a new hydrophilic polymer, Kollicoat IR, in the formulation of solid dispersions of itraconazole","volume":"30","author":"Janssens","year":"2007","journal-title":"Eur J Pharm Sci"},{"issue":"5","key":"10.1016\/j.xphs.2016.02.020_bib14","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1592\/phco.19.8.603.31529","article-title":"Itraconazole in cyclodextrin solution","volume":"19","author":"Stevens","year":"1999","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.xphs.2016.02.020_bib15","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1128\/AAC.36.2.477","article-title":"Effect of cyclodextrin on the pharmacology of antifungal oral azoles","volume":"36","author":"Hostetler","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.xphs.2016.02.020_bib16","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1365-2710.2001.00338.x","article-title":"Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics","volume":"26","author":"Willems","year":"2001","journal-title":"J\u00a0Clin Pharm Ther"},{"issue":"1-2","key":"10.1016\/j.xphs.2016.02.020_bib17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0378-5173(01)00867-5","article-title":"Processing factors in development of solid solution formulation of itraconazole for enhancement of drug dissolution and bioavailability","volume":"229","author":"Kapsi","year":"2001","journal-title":"Int J Pharm"},{"issue":"7","key":"10.1016\/j.xphs.2016.02.020_bib18","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1007\/s11095-008-9569-4","article-title":"Dissolution Media simulating conditions in the proximal human gastrointestinal tract: an update","volume":"25","author":"Jantratid","year":"2008","journal-title":"Pharm Res"},{"issue":"5","key":"10.1016\/j.xphs.2016.02.020_bib19","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1023\/A:1011910801212","article-title":"Evaluation of various dissolution Media for predicting in\u00a0vivo performance of class I and II drugs","volume":"15","author":"Galia","year":"1998","journal-title":"Pharm Res"},{"issue":"6","key":"10.1016\/j.xphs.2016.02.020_bib20","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1002\/jps.22033","article-title":"The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: mechanistic modeling and application to progesterone","volume":"99","author":"Dahan","year":"2010","journal-title":"J\u00a0Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2016.02.020_bib21","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1021\/mp200460u","article-title":"The solubility-permeability interplay when using cosolvents for solubilization: revising the way we use solubility-enabling formulations","volume":"9","author":"Miller","year":"2012","journal-title":"Mol Pharm"},{"issue":"9","key":"10.1016\/j.xphs.2016.02.020_bib22","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1038\/nprot.2007.303","article-title":"Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers","volume":"2","author":"Hubatsch","year":"2007","journal-title":"Nat Protoc"},{"issue":"suppl 1","key":"10.1016\/j.xphs.2016.02.020_bib23","first-page":"6","article-title":"Single- and multiple-dose pharmacokinetics of itraconazole oral solution in healthy men","volume":"54","author":"Tei","year":"2006","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.xphs.2016.02.020_bib24","first-page":"397","article-title":"Phase I study on itraconazole (ITZ), an oral triazole antifungal -Pharmacokinetics of ITZ in healthy subjects after single and multiple oral administrations","volume":"25","author":"Oguchi","year":"1991","journal-title":"Clin Rep"},{"issue":"1-2","key":"10.1016\/j.xphs.2016.02.020_bib25","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijpharm.2008.04.034","article-title":"Use of simulated intestinal fluid for Caco-2 permeability assay of lipophilic drugs","volume":"360","author":"Fossati","year":"2008","journal-title":"Int J Pharm"},{"issue":"6","key":"10.1016\/j.xphs.2016.02.020_bib26","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1007\/s11095-006-0162-4","article-title":"Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test","volume":"23","author":"Takano","year":"2006","journal-title":"Pharm Res"},{"issue":"7","key":"10.1016\/j.xphs.2016.02.020_bib27","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1002\/jps.22080","article-title":"Towards prediction of in\u00a0vivo intestinal absorption using a 96-well Caco-2 assay","volume":"99","author":"Skolnik","year":"2010","journal-title":"J\u00a0Pharm Sci"},{"issue":"9","key":"10.1016\/j.xphs.2016.02.020_bib28","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1002\/jps.24155","article-title":"In\u00a0vitro and in\u00a0vivo performance of different sized spray-dried crystalline itraconazole","volume":"104","author":"Kumar","year":"2015","journal-title":"J\u00a0Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2016.02.020_bib29","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jpba.2007.06.011","article-title":"Enhancement of dissolution amount and in\u00a0vivo bioavailability of itraconazole by complexation with beta-cyclodextrin using supercritical carbon dioxide","volume":"45","author":"Hassan","year":"2007","journal-title":"J\u00a0Pharm Biomed Anal"},{"issue":"4","key":"10.1016\/j.xphs.2016.02.020_bib30","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/bdd.546","article-title":"In\u00a0vitro and in\u00a0vivo comparative study of itraconazole bioavailability when formulated in highly soluble self-emulsifying system and in solid dispersion","volume":"28","author":"Park","year":"2007","journal-title":"Biopharm Drug Dispos"},{"issue":"2-3","key":"10.1016\/j.xphs.2016.02.020_bib31","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejps.2004.10.005","article-title":"Clinical study of solid dispersions of itraconazole prepared by hot-stage extrusion","volume":"24","author":"Six","year":"2005","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2016.02.020_bib32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1081\/DDC-100100324","article-title":"Bioavailability of itraconazole in rats and rabbits after administration of tablets containing solid dispersion particles","volume":"26","author":"Yoo","year":"2000","journal-title":"Drug Dev Ind Pharm"},{"issue":"7","key":"10.1016\/j.xphs.2016.02.020_bib33","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/BF02977355","article-title":"Preparation and characterization of solid dispersions of itraconazole by using aerosol solvent extraction system for improvement in drug solubility and bioavailability","volume":"28","author":"Lee","year":"2005","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.xphs.2016.02.020_bib34","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jconrel.2014.02.016","article-title":"Nanocrystal-based per-oral itraconazole delivery: superior in\u00a0vitro dissolution enhancement versus Sporanox\u00ae is not realized in in\u00a0vivo drug absorption","volume":"180","author":"Sarnes","year":"2014","journal-title":"J\u00a0Control Release"},{"key":"10.1016\/j.xphs.2016.02.020_bib35","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejps.2014.01.009","article-title":"The Biopharmaceutics Classification System: subclasses for in\u00a0vivo predictive dissolution (IPD) methodology and IVIVC","volume":"57","author":"Tsume","year":"2014","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2016.02.020_bib36","series-title":"Pellets Having a Core Coated With an Antifungal and a Polymer","author":"Vandecruys","year":"1998"},{"issue":"1","key":"10.1016\/j.xphs.2016.02.020_bib37","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1023\/A:1016062224568","article-title":"Estimation of the increase in solubility of drugs as a function of bile salt concentration","volume":"13","author":"Mithani","year":"1996","journal-title":"Pharm Res"},{"issue":"5","key":"10.1016\/j.xphs.2016.02.020_bib38","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1021\/mp100149j","article-title":"Physiological parameters for oral delivery and in\u00a0vitro testing","volume":"7","author":"Mudie","year":"2010","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2016.02.020_bib39","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejps.2013.10.015","article-title":"Early pharmaceutical profiling to predict oral drug absorption: current status and unmet needs","volume":"57","author":"Bergstr\u00f6m","year":"2014","journal-title":"Eur J Pharm Sci"},{"issue":"8","key":"10.1016\/j.xphs.2016.02.020_bib40","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1211\/jpp.58.8.0009","article-title":"Characterization of fasted-state human intestinal fluids collected from duodenum and jejunum","volume":"58","author":"Perez de la Cruz Moreno","year":"2006","journal-title":"J\u00a0Pharm Pharmacol"},{"issue":"6","key":"10.1016\/j.xphs.2016.02.020_bib41","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1021\/mp800042d","article-title":"Amorphous compositions using concentration enhancing polymers for improved bioavailability of itraconazole","volume":"5","author":"DiNunzio","year":"2008","journal-title":"Mol Pharm"},{"issue":"1-2","key":"10.1016\/j.xphs.2016.02.020_bib42","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijpharm.2008.01.049","article-title":"Ordered mesoporous silica induces pH-independent supersaturation of the basic low solubility compound itraconazole resulting in enhanced transepithelial transport","volume":"357","author":"Mellaerts","year":"2008","journal-title":"Int J Pharm"},{"issue":"2","key":"10.1016\/j.xphs.2016.02.020_bib43","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/jac\/dkg089","article-title":"A\u00a0randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution","volume":"51","author":"Johnson","year":"2003","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"10","key":"10.1016\/j.xphs.2016.02.020_bib44","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1002\/jps.23666","article-title":"In\u00a0vitro tools for evaluating novel dosage forms of poorly soluble, weakly basic drugs: case example ketoconazole","volume":"102","author":"Taupitz","year":"2013","journal-title":"J\u00a0Pharm Sci"},{"issue":"20","key":"10.1016\/j.xphs.2016.02.020_bib45","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1002\/elps.200700311","article-title":"Complexation of tauro- and glyco-conjugated bile salts with three neutral beta-CDs studied by ACE","volume":"28","author":"Holm","year":"2007","journal-title":"Electrophoresis"},{"issue":"3","key":"10.1016\/j.xphs.2016.02.020_bib46","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1248\/cpb.34.1395","article-title":"Interaction of beta-cyclodextrin with bile salts in aqueous solutions","volume":"34","author":"Miyajima","year":"1986","journal-title":"Chem Pharm Bull (Tokyo)"},{"issue":"4","key":"10.1016\/j.xphs.2016.02.020_bib47","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1211\/0022357022935","article-title":"Dissolution media simulating the intralumenal composition of the small intestine: physiological issues and practical aspects","volume":"56","author":"Vertzoni","year":"2004","journal-title":"J\u00a0Pharm Pharmacol"},{"key":"10.1016\/j.xphs.2016.02.020_bib48","unstructured":"Janssen Pharmaceuticals. Prescription information on Sporanox oral solution. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/020657s032lbl.pdf Accessed December 18, 2015."},{"issue":"1","key":"10.1016\/j.xphs.2016.02.020_bib49","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejps.2012.04.015","article-title":"Impact of FaSSIF on the solubility and dissolution-\/permeation rate of a poorly water-soluble compound","volume":"47","author":"Frank","year":"2012","journal-title":"Eur J Pharm Sci"},{"issue":"1-2","key":"10.1016\/j.xphs.2016.02.020_bib50","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ijpharm.2012.08.014","article-title":"Amorphous solid dispersion enhances permeation of poorly soluble ABT-102: true supersaturation vs. apparent solubility enhancement","volume":"437","author":"Frank","year":"2012","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2016.02.020_bib51","first-page":"5757","article-title":"The amorphous solid dispersion of the poorly soluble ABT-102 forms nano\/microparticulate structures in aqueous medium: impact on solubility","volume":"7","author":"Frank","year":"2012","journal-title":"Int J Nanomedicine"},{"issue":"1-2","key":"10.1016\/j.xphs.2016.02.020_bib52","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0378-5173(02)00347-2","article-title":"Common solubilizers to estimate the Caco-2 transport of poorly water-soluble drugs","volume":"246","author":"Takahashi","year":"2002","journal-title":"Int J Pharm"},{"issue":"1-2","key":"10.1016\/j.xphs.2016.02.020_bib53","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0378-5173(01)00897-3","article-title":"Simulated intestinal fluid as transport medium in the Caco-2 cell culture model","volume":"232","author":"Ingels","year":"2002","journal-title":"Int J Pharm"},{"issue":"2","key":"10.1016\/j.xphs.2016.02.020_bib54","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/03639040500465991","article-title":"Use of simulated intestinal fluids with Caco-2 cells and rat ileum","volume":"32","author":"Patel","year":"2006","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.xphs.2016.02.020_bib55","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejps.2014.11.010","article-title":"Evaluation of fasted state human intestinal fluid as apical solvent system in the Caco-2 absorption model and comparison with FaSSIF","volume":"67","author":"Wuyts","year":"2015","journal-title":"Eur J Pharm Sci"},{"issue":"7","key":"10.1016\/j.xphs.2016.02.020_bib56","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/bdd.1803","article-title":"Mechanistic analysis of solute transport in an in\u00a0vitro physiological two-phase dissolution apparatus","volume":"33","author":"Mudie","year":"2012","journal-title":"Biopharm Drug Dispos"},{"issue":"5","key":"10.1016\/j.xphs.2016.02.020_bib57","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1021\/mp100114a","article-title":"Application of a biphasic test for characterization of in\u00a0vitro drug release of immediate release formulations of celecoxib and its relevance to in\u00a0vivo absorption","volume":"7","author":"Shi","year":"2010","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2016.02.020_bib58","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/jps.20242","article-title":"Using a novel multicompartment dissolution system to predict the effect of gastric pH on the oral absorption of weak bases with poor intrinsic solubility","volume":"94","author":"Gu","year":"2005","journal-title":"J\u00a0Pharm Sci"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235491600383X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235491600383X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T20:04:24Z","timestamp":1788465864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235491600383X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":58,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S002235491600383X"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2016.02.020","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Evaluation of In\u00a0Vitro Drug Dissolution of Commercially Available Oral Dosage Forms for Itraconazole in Gastrointestinal Simulator With Biorelevant Media","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2016.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}